Your standard blood work includes creatinine, a waste product from muscle breakdown that your kidneys filter out. Doctors have used it for decades to estimate how well your kidneys are working. The problem is that creatinine depends heavily on how much muscle you carry. If you are older and losing muscle, creatinine can look reassuringly normal even while your kidneys are quietly failing. If you are young and muscular, it can look falsely high and trigger unnecessary worry. Cystatin C sidesteps that blind spot entirely.
Cystatin C (cystatin C) is a tiny protein made at a nearly constant rate by every cell in your body that has a nucleus. Your kidneys filter it freely from the blood, then break it down completely. Because its production does not depend on your muscle mass, diet, or sex, the amount circulating in your blood is driven almost entirely by how efficiently your kidneys are filtering. When filtering power drops, cystatin C rises, and it tends to rise earlier than creatinine does.
Creatinine has a strange quirk when it comes to predicting health outcomes. Both very low and very high creatinine levels are linked to higher mortality risk, forming a U-shaped curve. Very low creatinine often reflects frailty or muscle wasting rather than excellent kidney function, which means it can paint a misleadingly rosy picture in exactly the people who need closer monitoring.
Cystatin C does not have this problem. Its relationship with bad outcomes is linear: as levels climb, risk climbs with them, in a straightforward, predictable pattern. A large analysis pooling data from multiple population studies found that cystatin C reclassified risk more accurately than creatinine for both death and cardiovascular events, correctly reassigning 11% to 13% of people into risk categories that better matched what actually happened to them.
Cystatin C also begins to rise when the kidney filtering rate (called the glomerular filtration rate, or GFR) falls below roughly 88 mL/min/1.73 m², compared to about 75 mL/min/1.73 m² for creatinine. That gap means cystatin C can flag a decline in kidney performance while creatinine is still sitting in the normal range.
Elevated cystatin C is not just a kidney marker. It is one of the stronger predictors of cardiovascular trouble, and this association holds even in people whose creatinine-based kidney estimates look perfectly normal. A meta-analysis of over 38,800 people from the general population found that those in the highest category of cystatin C were about 2.7 times as likely to die from cardiovascular causes as those in the lowest category (pooled HR 2.74). Each standard-deviation bump in cystatin C increased cardiovascular mortality risk by 57%.
In people with established coronary artery disease, the numbers are similarly striking. A pooled analysis of 10 studies found that those with the highest cystatin C levels were about 2.2 times as likely to die from any cause and 2.2 times as likely to die from cardiovascular causes compared to those with the lowest levels. These associations held after adjusting for creatinine-based kidney function, suggesting cystatin C may be reflecting something beyond kidney filtering power alone, possibly blood vessel disease not yet causing symptoms or chronic low-grade inflammation.
The LIPID study, which followed nearly 7,900 people with stable heart disease for up to 16 years, confirmed this long-term pattern. People in the highest cystatin C quartile had about a 47% higher rate of major cardiovascular events compared to those in the lowest quartile, and this risk persisted even after accounting for combined creatinine-cystatin C kidney function estimates.
The dose-response relationship between cystatin C and death from any cause is remarkably consistent. A meta-analysis of 13 studies covering over 57,200 people found that those with the highest cystatin C levels were about twice as likely to die during the study period as those with the lowest levels (pooled HR 2.01). Every 0.1 mg/L increase in cystatin C was linked to a 7.3% increase in cardiovascular mortality.
Cancer mortality also tracks with cystatin C. In a study of nearly 14,000 adults aged 50 and older followed for a median of 5.8 years, those in the top quartile were about 62% more likely to die of cancer than those in the bottom quartile (HR 1.62). Among nearly 2,000 people with metabolic syndrome followed for over 15 years, the highest tertile of cystatin C carried a 72% higher cancer mortality risk (HR 1.72).
Cystatin C outperforms creatinine at detecting chronic kidney disease, or CKD. In head-to-head comparisons, cystatin C achieves a sensitivity of about 87% and specificity of about 87% for detecting CKD at the standard threshold, compared to creatinine's sensitivity of about 75%. It can also detect acute kidney injury one to two days earlier than creatinine.
The combined creatinine-cystatin C equation gives the most accurate estimate of true kidney filtering rate. This is because the non-kidney factors that distort each marker tend to cancel each other out when both are used together. The 2024 KDIGO guidelines and the 2025 VA/DoD CKD guidelines now recommend increased use of this combined approach.
In people with prediabetes or diabetes, cystatin C adds predictive power beyond standard metabolic markers. A study of over 85,000 participants found that elevated cystatin C predicted all-cause mortality (about double the risk), cardiovascular mortality (about 2.3 times the risk), and end-stage kidney disease (about 7.3 times the risk). It also predicted diabetic eye disease and small-vessel damage, offering a window into microvascular complications that standard kidney markers may miss.
One of the most clinically useful patterns is what happens when your creatinine-based and cystatin C-based kidney estimates disagree. When cystatin C suggests significantly worse kidney function than creatinine does, you are looking at a high-risk signal that creatinine alone would have missed completely.
A 2025 JAMA meta-analysis of over 820,000 outpatients found that when the cystatin C-based estimate was at least 30% below the creatinine-based estimate, the risk of dying or reaching kidney failure climbed sharply, with hazard ratios ranging from 1.3 to 1.7 compared to people whose two estimates agreed. A separate 2022 study of nearly 5,000 people with chronic kidney disease, followed for up to 15 years, found that cumulative mortality in the most discordant group reached roughly 60%. This discordance pattern identifies a population that standard testing, relying on creatinine alone, would have categorized as fine.
Cystatin C levels rise gradually with age, so a single set of cutpoints does not fit everyone perfectly. Men tend to run slightly higher than women at the same kidney function level. The ranges below are drawn from large population studies and serve as a useful starting orientation, but your own lab may report slightly different numbers depending on the assay it uses. Always compare your results within the same lab over time for the most meaningful trend.
| Tier | Range (mg/L) | What It Suggests |
|---|---|---|
| Optimal | 0.51 to 0.82 | Strong kidney filtering capacity, associated with the lowest cardiovascular and mortality risk in population studies. |
| Normal | 0.83 to 0.99 | Typical adult range. Kidney function is likely intact, though trending toward the upper end warrants monitoring. |
| Borderline | 1.00 to 1.12 | May reflect early, subtle decline in kidney filtering power. At this level, creatinine-based estimates often still look normal. |
| Elevated | Above 1.12 | Associated with meaningfully increased risk of cardiovascular events, kidney disease progression, and mortality across multiple large studies. |
These tiers are drawn from published research including the NHANES III study of over 7,500 U.S. adults and population studies establishing sex-specific ranges of 0.49 to 0.94 mg/L for women and 0.56 to 0.98 mg/L for men. Your lab may use different assays and cutpoints. Compare your results within the same lab over time for the most meaningful trend.
One factor that does not affect your cystatin C level is race. Unlike creatinine, cystatin C does not differ by race at the same measured kidney function, which is one reason guidelines increasingly favor it for kidney function estimation.
A single cystatin C result is a snapshot. A series of results over time is a trajectory, and the trajectory tells you far more than any individual number. Your cystatin C naturally fluctuates by about 3% to 7% from one draw to the next simply due to normal biological variation. This means a change of less than about 13% between two measurements may just be noise. A change exceeding roughly 13% to 31% (depending on the lab) likely reflects a real shift in kidney function.
A four-year study of diabetic patients with normal or mildly reduced kidney function showed that serial cystatin C measurements closely tracked actual changes in measured kidney filtering rate, with a strong statistical correlation of 0.77 between the trend in cystatin C and the trend in directly measured GFR. That is the kind of tracking power that can catch a slow, silent decline before it becomes a clinical problem.
Get a baseline measurement. If you are making lifestyle changes to protect your kidneys (or if you have any risk factors like diabetes, high blood pressure, or heart disease), retest in three to six months to see if you are moving in the right direction. After that, test at least annually. If your levels are in the borderline or elevated range, every six months is reasonable until you have established a stable trend.
Cystatin C is less susceptible to confounders than creatinine, but it is not immune. The biggest one is inflammation. Elevated C-reactive protein (a marker of systemic inflammation) and high white blood cell counts are independently associated with higher cystatin C levels, even after accounting for kidney function. If you are fighting an infection, recovering from surgery, or dealing with a flare of an inflammatory condition, your reading may overestimate your true level.
Corticosteroid use is another common confounder. Prednisolone at doses of roughly 12 mg per day or higher can push cystatin C up independent of any kidney change. If you are on steroids, your doctor should interpret your result in that context. Thyroid disease pulls the number in both directions: an overactive thyroid raises cystatin C, while an underactive thyroid lowers it. Getting your thyroid treated should normalize the effect.
Intense exercise can temporarily raise cystatin C by about 21% (less than the 41% spike creatinine sees after a marathon), likely because hard effort temporarily reduces blood flow to the kidneys. Avoid testing within 48 hours of a very hard workout to get a reading that reflects your baseline kidney function rather than a transient exercise effect.
One thing that does not affect your cystatin C, unlike creatinine: dietary protein intake. A randomized trial varying protein intake from 0.28 to 1.3 grams per kilogram of body weight per day found no effect on cystatin C, which makes it a more reliable marker if your diet varies significantly.
Evidence-backed interventions that affect your Cystatin C level
Cystatin C is best interpreted alongside these tests.